Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.

J Hematol Oncol · 2021 · PMC7809770 · PMID 33451349

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Likewise, the difference in time to first treatment (TTFT) for patients with mutated XPO1 relative to that of patients with wt XPO1 and unmutated IgHV or LP-CLL also did not reach statistical significance (Additional file 1 : figure S1C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.